User: Guest  Login
Title:

[Not Available].

Document type:
English Abstract; Journal Article
Author(s):
Klimek, L; Förster-Ruhrmann, U; Olze, H; Beule, A G; Chaker, A M; Hagemann, J; Huppertz, T; Hoffmann, T K; Dazert, S; Deitmer, T; Strieth, S; Wrede, H; Schlenter, W; Welkoborsky, H J; Wollenberg, B; Becker, S; Klimek, F; Sperl, A; Casper, I; Zuberbier, J; Rudack, C; Cuevas, M; Hintschich, C A; Guntinas-Lichius, O; Stöver, T; Bergmann, C; Pfaar, O; Gosepath, J; Gröger, M; Beutner, C; Laudien, M; Weber, R K; Hildenbrand, T; Hoffmann, A S; Bachert, C
Abstract:
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the nasal and paranasal mucosa. A Type-2 inflammation is described as the most common endotype. Since October 2019 the anti-IL-4/-IL-13 antibody dupilumab has been approved in Germany as an add-on therapy to intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps, when systemic corticosteroids alone or surgery do not provide adequate diseas...     »
Journal title abbreviation:
Laryngorhinootologie
Year:
2022
Journal volume:
101
Journal issue:
11
Pages contribution:
855-865
Fulltext / DOI:
doi:10.1055/a-1908-3074
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/36150698
Print-ISSN:
0935-8943
TUM Institution:
1212; 284; 599; Lehrstuhl für Molekulare Allergologie und Umweltforschung (Prof. Schmidt-Weber)
 BibTeX